Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 16/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.44 |
| ▸ | CDK9 | P50750 | 8/20 | 0.44 |
| ▸ | CDK7 | P50613 | 4/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22097432 | 0.82 | FLT3 (0.47) | FLT3PIK3CACCNT1CDK9CDK7 | |
| SCHEMBL15159190 | 0.79 | FLT3 (0.42) | FLT3PIK3CACCNT1CDK9CDK7 | |
| SCHEMBL13023124 | 0.79 | FLT3 (0.34) | FLT3PIK3CACCNT1CDK9CSNK2B | |
| SCHEMBL15951982 | 0.79 | FLT3 (0.53) | FLT3PIK3CACCNT1CDK9CDK7 | |
| SCHEMBL15951983 | 0.79 | FLT3 (0.53) | FLT3PIK3CACCNT1CDK9CDK7 | |
| SCHEMBL137570 | 0.76 | FLT3 (0.40) | FLT3PIK3CACCNT1CDK9CDK7 | |
| SCHEMBL14679359 | 0.76 | FLT3 (0.32) | FLT3CSNK2B | |
| SCHEMBL28574877 | 0.76 | FLT3 (0.44) | FLT3PIK3CACCNT1CDK9 | |
| SCHEMBL22097307 | 0.76 | FLT3 (0.39) | FLT3PIK3CACCNT1CDK9CDK7 | |
| SCHEMBL860486 | 0.75 | FYN (0.42) | CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4420732-A2 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG Pharmaceutical Co., Ltd. (KR) | 2024-08-28 | — | — | EP | disclosed |
| EP-3233863-B1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG PHARMACEUTICAL CO LTD (KR) | 2024-04-10 | — | — | EP | disclosed |
| CN-112979654-B | Heteroaryl fused ring compounds, preparation method and application thereof | 赛诺哈勃药业（成都）有限公司 | 2024-03-19 | — | — | CN | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4100381-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2022-12-14 | — | — | EP | disclosed |
| CN-115413275-A | Substituted 1,1 , -biphenyl compounds and methods of use thereof | 爱彼特生物制药公司 | 2022-11-29 | — | — | CN | disclosed |
| WO-2021158481-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| CN-112979654-A | Heteroaryl fused ring compound, preparation method and application thereof | 成都倍特药业有限公司 | 2021-06-18 | — | — | CN | disclosed |
| CN-107207514-B | Fused heteroaryl compounds and their use as TRK inhibitors | 康联制药有限公司 | 2020-01-24 | — | — | CN | disclosed |
| EP-2958564-B1 | HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS | CALITOR SCIENCES LLC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| WO-2011031979-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031979-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| WO-2010135581-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135581-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | PIM2, PIM1, PIM3 | FLT3 63/4885PIK3CA 188/4885CCNT1 321/4885 |
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | FLT3 39/4885PIK3CA 181/4885CCNT1 400/4885 |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | FLT3 1762/4885PIK3CA 2111/4885CCNT1 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.